| JPM THEMATICS-GENETIC THERAPIES C (DIST) USD | RVI BIOTECNOLOGÍA | 66,640420 | 10/07/2026 | 17,03% | 20,42% | ** |
| JPM THEMATICS-GENETIC THERAPIES D (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 92,110000 | 10/07/2026 | 12,85% | 16,54% | ** |
| JPM THEMATICS-GENETIC THERAPIES D (ACC) USD | RVI BIOTECNOLOGÍA | 74,619423 | 10/07/2026 | 16,16% | 16,29% | ** |
| JPM THEMATICS-GENETIC THERAPIES I2 (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 114,680000 | 10/07/2026 | 13,78% | 22,06% | ** |
| JPM THEMATICS-GENETIC THERAPIES I2 (ACC) USD | RVI BIOTECNOLOGÍA | 84,225722 | 10/07/2026 | 17,13% | 21,96% | ** |
| JPM THEMATICS-GENETIC THERAPIES I (ACC) EUR | RVI BIOTECNOLOGÍA | 82,540000 | 10/07/2026 | 16,95% | 21,88% | ** |
| JPM THEMATICS-GENETIC THERAPIES I (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 80,620000 | 10/07/2026 | 13,73% | 21,73% | ** |
| JPM TOTAL EMERGING MARKETS INCOME A (ACC) EUR | MIXTO AGRESIVO GLOBAL | 152,890000 | 10/07/2026 | 14,21% | 44,22% | ***** |
| JPM TOTAL EMERGING MARKETS INCOME A (ACC) USD | MIXTO AGRESIVO GLOBAL | 152,659668 | 10/07/2026 | 14,32% | 43,94% | ***** |
| JPM TOTAL EMERGING MARKETS INCOME A (DIST) EUR | MIXTO AGRESIVO GLOBAL | 110,270000 | 10/07/2026 | 14,20% | 31,48% | ** |
